GlassScriptPhysician profile
William L Miller
NPI 1407817042
$1,150.84
in general payments reported to CMS, 2019-2025
24 companies · $280 in 2025
The $280 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $314 · 2023: $251 · 2024: $306 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $836.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $174.50 | 2022-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $160.55 | 2022-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $92.91 | 2022-2025 | Rexulti |
| Lilly USA, LLC | $89.76 | 2022-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $86.10 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.12 | 2022-2024 | Jardiance |
| Phathom Pharmaceuticals, INC. | $61.59 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $58.01 | 2023-2024 | Ozempic, Wegovy |
| Daiichi Sankyo INC. | $57.86 | 2022-2024 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $40.02 | 2022-2023 | |
| Corcept Therapeutics | $37.28 | 2024 | Korlym |
| Abiomed | $29.87 | 2024 | Impella |
| Amgen INC. | $29.42 | 2022-2024 | Otezla, Repatha |
| Vanda Pharmaceuticals INC. | $23.49 | 2024 | Fanapt, Hetlioz |
| Horizon Therapeutics Plc | $23.42 | 2023 | Krystexxa |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $18.29 | 2024 | |
| Glaxosmithkline, LLC. | $16.30 | 2025 | Arexvy, Shingrix |
| Esperion Therapeutics, INC. | $15.72 | 2022 | |
| Lundbeck LLC | $14.88 | 2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $13.48 | 2025 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $12.60 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.71 | 2022 | |
| Organon LLC | $8.46 | 2025 | Nexplanon |
| Dynavax Technologies Corporation | $6.50 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.